There are now eight FDA-approved ADCs for the treatment of cancer, including three with accelerated approval within the last year. Recently approved ADCs, as well as many of those in development, seek ...
Probody drug conjugates, immune-stimulating antibody conjugates, engineered toxin bodies, radioligand conjugates, and so on comprise the new wave of molecules in clinical development, seeking to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results